Aster DM Healthcare FY26: Growth, Margin Expansion, and a Merger That Changes the Scale

Aster DM Healthcare ended FY26 with strong operating momentum in India and a clear strategic pivot towards scale through its proposed merger with Quality Care India Limited (QCIL). In Q4 FY26, Aster’s revenue from operations rose 18 percent year on year to INR 1,182 crore, while operating EBITDA grew 26 percent to INR 244 crore. Normalised PAT post non-controlling interest increased 32 percent to INR 140 crore. The quarter also carried the impact of the newly operationalised MIMS Kasargod hospital, which is still in ramp-up. Excluding Kasargod, the company reported operating EBITDA of INR 253 crore and margin of 21.7 percent.

In the investor presentation, management also highlighted proforma combined numbers for Aster and QCIL, offering a preview of the earnings profile of the merged platform. On a proforma basis, Q4 FY26 revenue was INR 2,361 crore, up 18 percent year on year, and operating EBITDA rose 25 percent to INR 517 crore. Operating margins were reported at 21.9 percent and RoCE improved to 21.1 percent.

Aster India performance: volume growth plus better mix

Aster’s growth in Q4 FY26 was driven by higher patient throughput and improving realisation. Total patient volumes grew 15 percent year on year and ARPP for inpatients rose 9 percent. Kerala continued to be the biggest earnings engine. The Kerala cluster delivered Q4 revenue of INR 604 crore, up 21 percent year on year. Excluding Kasargod, Kerala revenue grew 18 percent and operating EBITDA margin was reported at 25.6 percent.

Karnataka and Maharashtra saw revenue growth of 11 percent to INR 394 crore, but profitability expanded faster. Operating EBITDA grew 25 percent to INR 97 crore and margin improved to 24.5 percent. Management attributed realisation improvement to a higher share of complex procedures and a deliberate de-empanelment of low-yielding schemes at Aster Aadhar.

Andhra and Telangana stood out for operating leverage. Q4 revenue rose 30 percent to INR 151 crore and operating EBITDA more than doubled to INR 28 crore, with margins improving to 18.3 percent.

Aster also called out strong growth in medical value travel. MVT revenue increased 41 percent year on year, with Kerala MVT up 51 percent, helped by higher inflows from Maldives and other markets even as some Middle East corridors softened.

Financial summary

QCIL FY26: strong growth and internal synergies before merger

QCIL reported FY26 revenue of INR 4,630 crore, up 17 percent year on year. Operating EBITDA grew 24 percent to INR 1,066 crore, with margins of 23.0 percent. In Q4 FY26, QCIL revenue was INR 1,178 crore and operating EBITDA was INR 272 crore, with margin at 23.1 percent.

Management highlighted multiple operating levers: procurement centralisation, in-sourcing initiatives, clinical hiring, and focus on higher-acuity programs. QCIL also disclosed that procurement synergies across QCIL entities delivered about INR 85 crore plus of EBITDA uplift in FY26. The Nagercoil unit, launched in October 2024, was cited as having ramped to an EBITDA margin of 28.5 percent within six quarters.

Merger progress, synergy targets, and capacity pipeline

The merger between Aster and QCIL remains subject to NCLT approval. The company reported that shareholders approved the merger proposal with 96.68 percent of votes cast in favour. CCI approval and stock exchange no-objection have been received, and the NCLT application was filed on December 11, 2025. Management stated the merger is expected to be completed in Q1 FY27.

On synergies, the presentation identified an EBITDA upside potential of 10 to 15 percent in the near term, expressed as a percent of FY24 proforma EBITDA of the merged entity. The synergy framework covered integrated doctor models, revenue synergies such as international patient initiatives and insurer coverage, supply chain rationalisation, and lower overheads.

Capacity expansion is another core part of the story. At the combined level, the proforma network stood at 10,623 beds as of March 31, 2026, with a pipeline of 4,445 beds that would take capacity to 15,068 beds. The plan is weighted towards brownfield expansion, which management stated increased to 56 percent of the pipeline.

At Aster India level, bed capacity was 5,449 as of March 31, 2026. Aster Whitefield added a dedicated women and children block of 159 beds in April 2026 and Aster Ramesh Ongole added 75 beds in April 2026. The company’s pipeline totals 2,728 beds to take capacity to 8,177 beds over FY27 and beyond.

What investors should track next

The documents show a business in a strong operating phase. Aster is growing volumes and realisation, and the mature hospital base continues to support profitability. QCIL is also showing strong execution, with margins above 23 percent and disclosed benefits from internal procurement synergies.

The main swing factor is the merger closure and integration. The proforma numbers indicate a platform with revenue of INR 9,273 crore and operating EBITDA of INR 2,013 crore in FY26, with RoCE of about 21 percent. But the company has also cautioned that QCIL numbers are indicative and the combined proforma is subject to finalisation and audit adjustments.

If the merger closes on the stated timeline and the synergy roadmap is executed with discipline, the combined entity would move into a materially higher scale bracket while maintaining margins above 20 percent. The next few quarters will likely be watched for NCLT progress, integration milestones, and early evidence of synergy capture in supply chain and overhead optimisation.